Home
/
Summit Therapeutics Inc.
/
Financials
/
Quarterly
Summit Therapeutics Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Summit Therapeutics Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2024
Sep 30, 2024
$0
Oct 30, 2024
Q3
2024
Sep 30, 2023
$0
Oct 30, 2024
Q2
2023
Jun 30, 2023
$0
Aug 9, 2023
Q1
2023
Mar 31, 2023
$0
May 11, 2023
Q3
2023
Sep 30, 2022
$220.0K
Nov 7, 2023
Q2
2023
Jun 30, 2022
$235.0K
Aug 9, 2023
Q1
2023
Mar 31, 2022
$250.0K
May 11, 2023
Q3
2022
Sep 30, 2021
$1.31M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$57.0K
Aug 11, 2022
Q1
2022
Mar 31, 2021
$192.0K
May 11, 2022
Q3
2021
Sep 30, 2020
$181.0K
Nov 15, 2021
Q2
2021
Jun 30, 2020
$170.0K
Aug 12, 2021
Q1
2021
Mar 31, 2020
$324.0K
May 17, 2021
Q3
2020
Sep 30, 2019
$148.0K
Nov 16, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($231.79M)
Oct 20, 2025
Q3
2025
Jun 30, 2025
($565.71M)
Oct 20, 2025
Q2
2025
Jun 30, 2025
($565.71M)
Aug 11, 2025
Q2
2025
Mar 31, 2025
($62.91M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($62.91M)
May 1, 2025
Q3
2025
Mar 31, 2025
($62.91M)
Oct 20, 2025
Q3
2025
Sep 30, 2024
($56.25M)
Oct 20, 2025
Q2
2025
Jun 30, 2024
($60.39M)
Aug 11, 2025
Q3
2025
Jun 30, 2024
($60.39M)
Oct 20, 2025
Q3
2025
Mar 31, 2024
($43.47M)
Oct 20, 2025
Q1
2025
Mar 31, 2024
($43.47M)
May 1, 2025
Q2
2025
Mar 31, 2024
($43.47M)
Aug 11, 2025
Q3
2024
Sep 30, 2023
($21.27M)
Oct 30, 2024
Q2
2024
Jun 30, 2023
($14.72M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($542.38M)
May 1, 2024
Q3
2023
Sep 30, 2022
($21.39M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($16.77M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($21.40M)
May 11, 2023
Q3
2022
Sep 30, 2021
($19.60M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($24.42M)
Aug 11, 2022
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2024
Sep 30, 2024
($58.38M)
Oct 30, 2024
Q2
2024
Jun 30, 2024
($59.62M)
Aug 6, 2024
Q1
2024
Mar 31, 2024
($42.39M)
May 1, 2024
Q3
2024
Sep 30, 2023
($20.49M)
Oct 30, 2024
Q2
2024
Jun 30, 2023
($15.79M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($537.15M)
May 1, 2024
Q3
2023
Sep 30, 2022
($16.94M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($12.69M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($22.16M)
May 11, 2023
Q3
2022
Sep 30, 2021
($19.49M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($23.73M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($16.92M)
May 11, 2022
Q3
2021
Sep 30, 2020
($16.94M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($15.36M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($9.34M)
May 17, 2021
Q3
2020
Sep 30, 2019
($6.19M)
Nov 16, 2020